Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2018 08:00 ET | Source: MediWound Ltd.

MediWound to Host Second Quarter 2018 Financial Results Conference Call on August 7 at 8:30 a.m. Eastern Time

YAVNE, Israel, July 31, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
June 19, 2018 07:00 ET | Source: MediWound Ltd.

MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.

Study fully funded by BARDA YAVNE, Israel, June 19, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address...
June 11, 2018 07:00 ET | Source: MediWound Ltd.

MediWound Completes Enrollment in NexoBrid® U.S. Phase 3 DETECT Study

Top-line acute data currently expected around year end 2018 YAVNE, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing...
June 04, 2018 07:00 ET | Source: MediWound Ltd.

NexoBrid® Receives Marketing Authorization From South Korea’s Ministry of Health

Exclusive distributor BL&H Co., Ltd. plans commercial launch in second half of 2018 YAVNE, Israel, June 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated...
May 29, 2018 08:00 ET | Source: MediWound Ltd.

FDA Clears Development Pathway for NexoBrid® for Sulfur Mustard Injuries

YAVNE, Israel, May 29, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
May 10, 2018 07:00 ET | Source: MediWound Ltd.

MediWound Reports First Quarter 2018 Financial Results

Anticipates completion of enrollment of Phase 3 DETECT Study of NexoBrid® around mid-2018 Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, May 10, 2018 (GLOBE NEWSWIRE) --...
May 04, 2018 08:00 ET | Source: MediWound Ltd.

MediWound to Host First Quarter 2018 Financial Results Conference Call on May 10 at 8:30 a.m. Eastern Time

YAVNE, Israel, May 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
April 09, 2018 08:00 ET | Source: MediWound Ltd.

MediWound’s NexoBrid® to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago

Presentations highlight European consensus around the efficacy and benefits of NexoBrid use in severe burns YAVNE, Israel, April 09, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a...
March 19, 2018 07:00 ET | Source: MediWound Ltd.

MediWound Reports Fourth Quarter and Fiscal Year 2017 Financial Results

NexoBrid® sales grow 60% in 2017 vs. 2016 Raised gross proceeds of $25.2 million through an equity offering to fund EscharEx® clinical plan Awarded additional $32 million from BARDA bringing...
March 13, 2018 16:05 ET | Source: MediWound Ltd.

MediWound to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call on March 19 at 8:30 a.m. Eastern Time

YAVNE, Israel, March 13, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...